Holen Sie sich die Stockscreener-App
7.29
8.00%
0.54
Schlusskurs vom Vortag:
$6.75
Offen:
$6.73
24-Stunden-Volumen:
3.34M
Relative Volume:
10.16
Marktkapitalisierung:
$188.10M
Einnahmen:
$34.26M
Nettoeinkommen (Verlust:
$-46.61M
KGV:
-1.4072
EPS:
-5.1806
Netto-Cashflow:
$-62.01M
1W Leistung:
+7.05%
1M Leistung:
-3.83%
6M Leistung:
+72.34%
1J Leistung:
+76.09%
1-Tages-Spanne:
$6.73
$7.60
1-Wochen-Bereich:
$6.565
$7.60
52-Wochen-Spanne:
$3.53
$8.82
Precision Biosciences Inc Stock (DTIL) Company Profile
Firmenname
Precision Biosciences Inc
Sektor
Branche
Telefon
919-314-5512
Adresse
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
7.29 | 188.10M | 34.26M | -46.61M | -62.01M | -5.1806 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | Eingeleitet | Guggenheim | Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-06-09 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Stifel | Buy |
| 2020-02-25 | Eingeleitet | William Blair | Outperform |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-22 | Eingeleitet | Barclays | Overweight |
| 2019-04-22 | Eingeleitet | Goldman | Buy |
| 2019-04-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-04-22 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Precision Biosciences Inc Aktie (DTIL) Neueste Nachrichten
Precision BioSciences, Inc. Actuals & Estimates (DUS:PBS0) - TradingView
Price to sales forward of Precision BioSciences, Inc. – NASDAQ:DTIL - TradingView
Precision BioSciences Inc (DTIL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Price to earnings forward of Precision BioSciences, Inc. – NASDAQ:DTIL - TradingView
Precision BioSciences, Inc. Actuals & Estimates (NASDAQ:DTIL) - TradingView
Enterprise value to EBIT forward of Precision BioSciences, Inc. – LS:A400AS - TradingView
DTIL Forecast — Price Target — Prediction for 2027 - TradingView
Precision BioSciences earnings calendar and gene-editing focus, shares remain a small-cap biotech pl - Ad-hoc-news.de
Precision BioSciences Inc (DTIL) Institutional Confidence - TradingKey
Precision BioSciences Inc (DTIL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Precision BioSciences (DTIL) AGM 2026 Summary - Quartr
Precision BioSciences Inc (DTIL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Precision BioSciences Inc (DTIL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Precision BioSciences Inc (DTIL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Precision BioSciences Inc (DTIL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Precision BioSciences Inc (DTIL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Precision BioSciences Inc (DTIL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Precision BioSciences Extends Term Loan Maturity to 2029 - TipRanks
Precision BioSciences Extends Term Loan Maturity to 2029 in Amendment With Banc of California - TradingView
Precision BiosciencesEnters First Amendment To Loan And Security Agreement With Banc Of CaliforniaSEC Filing - TradingView
Precision BioSciences (NASDAQ: DTIL) amends loan and extends term to 2029 - Stock Titan
Precision BioSciences, Inc. Amends Loan and Security Agreement with Banc of California - marketscreener.com
Oppenheimer Maintains Precision BioSciences(DTIL.US) With Buy Rating, Raises Target Price to $20 - Moomoo
DTIL Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlitetm in Landmark CREDENCE Trial - Lelezard
[Form 4] PRECISION BIOSCIENCES INC Insider Trading Activity - Stock Titan
Director at Precision Bio (NASDAQ: DTIL) receives 20,979 restricted stock units - Stock Titan
Precision Biosciences (DTIL) director receives grant of 20,979 restricted stock units - Stock Titan
Precision BioSciences (DTIL) director receives grant of 20,979 RSUs - Stock Titan
Precision BioSciences stock (US74019P1084): shares edge higher amid biotech volatility - AD HOC NEWS
H.C. Wainwright Reaffirms Their Buy Rating on Precision BioSciences (DTIL) - The Globe and Mail
Executive at Precision BioSciences (DTIL) receives 57,389 RSU compensation award - Stock Titan
Precision BioSciences (DTIL) awards 107,604 RSUs to General Counsel - Stock Titan
Precision BioSciences (NASDAQ: DTIL) CEO receives 573,888 restricted stock units - Stock Titan
Precision BioSciences (DTIL) Jefferies Global Healthcare 2026 Conference Summary - Quartr
Precision BioSciences (DTIL) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Tyra Biosciences Expands Precision Oncology Clinical Pipeline - asatunews.co.id
Analysts Conflicted on These Healthcare Names: MannKind (MNKD), Biohaven Ltd. (BHVN) and Precision BioSciences (DTIL) - The Globe and Mail
DTIL Stock Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
Guggenheim Maintains Precision BioSciences(DTIL.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 - New Castle News
Precision BioSciences Shareholders Approve Incentive Plan and Directors - The Globe and Mail
DTIL Reiterates by HC Wainwright & Co. -- Price Target Maintained at $60 - GuruFocus
Precision BioSciences (DTIL) Unveils Groundbreaking Data on PBGE - GuruFocus
Precision BioSciences Put Its ARCUS Gene Editing Data Front And Center - Finimize
Precision BioSciences, Inc. (DTIL) Discusses Updates on PBG and HBV Program and ELIMINATE-B Trial ResultsSlideshow (NASDAQ:DTIL) 2026-05-27 - Seeking Alpha
Precision BioSciences stock jumps on hepatitis B trial data By Investing.com - Investing.com South Africa
Precision BioSciences stock jumps on hepatitis B trial data - Investing.com
Precision BioSciences Reports Promising New Hepatitis B Trial Data - TipRanks
Why Is Precision BioSciences Stock Gaining Wednesday?Precision BioSciences (NASDAQ:DTIL) - Benzinga
Precision BioSciences Approves Amendments to 2019 Incentive Award Plan and Certificate of Incorporation - minichart.com.sg
Finanzdaten der Precision Biosciences Inc-Aktie (DTIL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Precision Biosciences Inc-Aktie (DTIL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Amoroso Michael | President and CEO |
Feb 18 '26 |
Sale |
3.84 |
20,559 |
78,947 |
243,392 |
| Kelly John Alexander | Chief Financial Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
27,584 |
0 |
134,032 |
| Kelly John Alexander | Chief Financial Officer |
Feb 18 '26 |
Sale |
3.84 |
8,149 |
31,292 |
125,883 |
| Scimeca Dario | General Counsel and Secretary |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
61,382 |
| Scimeca Dario | General Counsel and Secretary |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
56,457 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
126,851 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
121,926 |
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):